Year All20242023202220212020 Jun 08, 2022 Shelia Violette, Founder and Chief Scientific Officer of Q32 Bio, to Present at the Keystone Symposia "Resolution of Inflammation" Conference PDF Version May 26, 2022 Q32 Bio Initiates First-in-Human Phase 1 Clinical Study of ADX-097 for the Treatment of Complement Disorders PDF Version Dec 13, 2021 Q32 Bio Presents Preclinical Data Highlighting the Design and Characterization of Lead Program for Innate Immunity, ADX-097, at the 28th International Complement Virtual Workshop 2021 PDF Version Nov 08, 2021 Q32 Bio Presents Preclinical Data Supporting Next Generation Complement Inhibitor, ADX-097, at the American Society of Nephrology Kidney Week 2021 PDF Version Oct 18, 2021 Q32 Bio to Present Preclinical Data on Next Generation Complement Inhibitor, ADX-097, at the American Society of Nephrology Kidney Week 2021 PDF Version Aug 03, 2021 Q32 Bio Announces Appointment of Kathy LaPorte to its Board of Directors PDF Version Jul 07, 2021 Q32 Bio Appoints Adam Cutler as Chief Financial Officer PDF Version May 27, 2021 Q32 Bio to Present at the Jefferies Virtual Healthcare Conference PDF Version Mar 09, 2021 Q32 Bio Appoints Dr. Jason Campagna as Chief Medical Officer PDF Version Dec 22, 2020 Q32 Bio Appoints Experienced Biopharmaceutical Leader Mark Iwicki as Chairman of Board of Directors PDF Version
Jun 08, 2022 Shelia Violette, Founder and Chief Scientific Officer of Q32 Bio, to Present at the Keystone Symposia "Resolution of Inflammation" Conference PDF Version
May 26, 2022 Q32 Bio Initiates First-in-Human Phase 1 Clinical Study of ADX-097 for the Treatment of Complement Disorders PDF Version
Dec 13, 2021 Q32 Bio Presents Preclinical Data Highlighting the Design and Characterization of Lead Program for Innate Immunity, ADX-097, at the 28th International Complement Virtual Workshop 2021 PDF Version
Nov 08, 2021 Q32 Bio Presents Preclinical Data Supporting Next Generation Complement Inhibitor, ADX-097, at the American Society of Nephrology Kidney Week 2021 PDF Version
Oct 18, 2021 Q32 Bio to Present Preclinical Data on Next Generation Complement Inhibitor, ADX-097, at the American Society of Nephrology Kidney Week 2021 PDF Version
Dec 22, 2020 Q32 Bio Appoints Experienced Biopharmaceutical Leader Mark Iwicki as Chairman of Board of Directors PDF Version